Immutep Limited American Depositary Shares (IMMP)

Price$0.38

Value ScoreB

Growth ScoreB

Momentum ScoreF

Favorite Metrics

Price vs S&P 500 (26W)-89.46%

Price vs S&P 500 (4W)-17.23%

VGM Score48.53

Market Capitalization$52.13M

All Metrics

Book Value / Share (Quarterly)$0.05

P/TBV (Annual)2.57x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-49.93%

Cash Flow / Share (Quarterly)$0.00

Price vs S&P 500 (YTD)-95.05%

Net Profit Margin (TTM)-2030.67%

EPS (TTM)$-0.04

10-Day Avg Trading Volume35.16M

EPS Excl Extra (TTM)$-0.04

Revenue Growth (5Y)-66.35%

EPS (Annual)$-0.03

ROI (Annual)-42.29%

Net Profit Margin (5Y Avg)-31067.06%

Cash / Share (Quarterly)$0.05

Revenue Growth QoQ (YoY)17606.36%

ROA (Last FY)-39.13%

Revenue Growth TTM (YoY)7574.00%

EBITD / Share (TTM)$-0.04

ROE (5Y Avg)-33.92%

Operating Margin (TTM)-2153.84%

Cash Flow / Share (Annual)$-0.02

P/B Ratio0.75x

P/B Ratio (Quarterly)6.41x

EV / Revenue (TTM)0.52x

Net Interest Coverage (TTM)-2.30x

ROA (TTM)-55.17%

EPS Incl Extra (Annual)$-0.03

Current Ratio (Annual)11.69x

Quick Ratio (Quarterly)2.91x

3-Month Avg Trading Volume34.09M

52-Week Price Return-82.55%

Tangible BV / Share (Quarterly)$0.04

P/S Ratio (Annual)1226.06x

Asset Turnover (Annual)0.00x

52-Week High$0.47

Operating Margin (5Y Avg)-34985.03%

EPS Excl Extra (Annual)$-0.03

CapEx CAGR (5Y)86.31%

Tangible BV CAGR (5Y)49.61%

26-Week Price Return-81.54%

Quick Ratio (Annual)11.02x

13-Week Price Return-87.53%

Total Debt / Equity (Annual)0.01x

Current Ratio (Quarterly)2.97x

Enterprise Value$1.52M

Asset Turnover (TTM)0.03x

Book Value / Share Growth (5Y)7.93%

Pretax Margin (Annual)-102219.92%

Cash / Share (Annual)$0.06

3-Month Return Std Dev263.80%

ROE (Last FY)-42.77%

Net Interest Coverage (Annual)-101.51x

EPS Basic Excl Extra (Annual)$-0.03

Receivables Turnover (TTM)0.26x

EV / Free Cash Flow (TTM)52.42x

Total Debt / Equity (Quarterly)0.01x

EPS Incl Extra (TTM)$-0.04

Receivables Turnover (Annual)0.10x

ROI (TTM)-68.40%

P/S Ratio (TTM)17.83x

Pretax Margin (5Y Avg)-31067.05%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$0.07

Price vs S&P 500 (52W)-106.91%

Year-to-Date Return-88.43%

5-Day Price Return-9.43%

EPS Normalized (Annual)$-0.03

ROA (5Y Avg)-31.07%

Net Profit Margin (Annual)-102219.92%

Month-to-Date Return-9.43%

Cash Flow / Share (TTM)$-0.03

EBITD / Share (Annual)$-0.03

Operating Margin (Annual)-116703.91%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-33.31%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.04

P/TBV (Quarterly)6.81x

P/B Ratio (Annual)2.44x

Pretax Margin (TTM)-2030.67%

Book Value / Share (Annual)$0.07

Price vs S&P 500 (13W)-95.79%

Beta2.81x

Revenue / Share (TTM)$0.00

ROE (TTM)-69.20%

52-Week Low$0.03

vGradeB

gGradeB

mGradeF

vgmGradeC

Show chart for

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.10

3.63

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
IMMPImmutep Limited American Depositary Shares	B	B	F	$0.38
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Immutep is a Phase 3 clinical-stage biotechnology company developing LAG-3 immunotherapies to treat cancer and autoimmune diseases. Its lead candidate, eftilagimod alfa (efti), is in a registrational Phase 3 trial for first-line non-small cell lung cancer. The company's diversified pipeline includes additional LAG-3-based programs targeting various solid tumors and autoimmune indications.